MYND Life Sciences Submits Patent Applications For Depression & Neuropsychiatric Disorder Drug

MYND Life Sciences Inc. a drug research and development company focused on developing novel psychedelic drugs filed additional provisional patents that utilize various psilocybin analogs to target clinical depression. The patent application addresses methods of inhibiting neuroinflammation to potentially treat a wide variety of neuropsychiatric disorders, including but not limited to major depressive disorder (MDD), schizophrenia, anxiety, bipolar disorder, obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD).

The company has two flagship drugs in its development pipeline; MYND-604 and MYND-778. MYND-604 is the lead candidate being developed as a novel oral dosage to treat MDD . . .